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Methods: Rabbita were randomized to receive 100 mgikg of MOR-14
or an equivalent volume of saline 10 min before iachemia. Infarct size was
aaesssad by TTC at 48 hr of repeffusion following 30 min ischemia and was
expressad as a percent of area at riak (lN/AAR) (MOR-14: n = 10, saline: n =
10). a-1,8-glucosidase activity (pmol glucose incorporated into glycogen per
min per mg protein), and glycogen and lactate content (mglg tissue) in the
ischemic myocardium were assesaed at 30 min of ischemia (MOR-14: n =
11,saline: n = 11).
Resufts: Date are given below.
IN/AAR(%) a.1,6-Glucosidsse Glycogsn Lactate
MOR-14 14& 2* 1.7 * 0.2” 1.3 * 0.1” 2.6 + 0.2”
Saline 45* 5 7.s * 1.4 0.4 * 0.1 3,9 * 0.2
(mean + SEM, “p <0.05 vs. saline)
Cone/usions:Pre-ischemic treatment with MOR-14inhibited cel,6-glucosidase
activity in the heart, presewad the glycogen content, attenuated the Iactata
accumulation, and reduced the infarct size by 69Y0 without affecting the
hemodynamice or regional blood flow. The compound will be useful forphar-
macologicsl preconditioning againat iachemia.
988-95 Antimyosin Immunoliposomes Prevent and
Reverse Cardiocyte Death Induced by Hypoxia up
to 5 Days
1.Vural, J. Narula, V. Torchilin, B.-A. Khaw. Northeastern University and
Massachusetts Geneml Hospital, Boston, USA
Antimyoain-immunoliposomes (IL) have been shown to presewe cerdio-
cyte viability by sealing hypoxia-induced aarcdemmal lesions. To determine
whether protection can be extendad to longer periods of hypoxia, H9C2 rat
cardiocytas (2 x Id) in culture were subjected to hypoxia for 1-5 days with
IL and plain Iiposomea (PL). The cell viability of cardiocytea asaessad by
3H-Thymidine (3HT) upfake was compared with hypoxic controls (HC) and
cells cultured in normoxic condition (NC). After 24 H, viability of NC cells
(254 + 18%) waa similar to H9C2 hypoxic cella treated with IL (225 + 13%).
Viability of 24 h hypoxic cells treated with PL (9– + 13%) or HC (- O%)was
significantly lower. Viability of IL treatad cells at 2, 3,4 and 5 days waa 89 +
12, 49 ~ 8, 15 + 8 and 8 + 4%, respectively, campered to 4 + 1, 1 + 0.2,
0.2 +0.1 and 0.5 + 0.4% of PL treated calls. Since 3HT uptake of IL-treated
hypoxic cells increased by 250% aimilarto NC cells, ILtreatment must allow
the csrdiocytes to continua call replication aven under severe hypoxia.
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Thia study shows the potential of IL-based aalvage of ischemicelly com-
promised myocardial cella.
1988-96[ Monoclinal AntibOdyto C5inhibits C5a And C5b-9
Generation Without Inhibition of C3 Cleavage and
Significantly Limite Myocardial Iechemia and
Reperfusion Induced Tiasue Damage
A. Vakeva, S.A. Rollina, L.A. Matis, G.L. Stahl. 6rfgham and Women’s
Hospital, Boston, MA, USA, Alexion Pharmaceuticals, New Haven, CX USA
The role of early (C3a, iC3b) vs late (C5a, C5b-9) complement components
in myocerdial ischemiaheperfusion (MVR) injury has not been established.
In order to eeeees the contribution of C5a and C5b-9 in a ret model of
Mi/R injury, monoclinal antibodies (Mab) were reiaed againat rat C5 and
characterized. Mabl or Mab2 bound ret C5, but only Mabl blocked C5a
and C5b-9 generation. In a rat model of myocerdial ischemia (34 rein) and
rep#usion (4 hre), pretreatment with Mabl (n =4; one hr bafora iachemia)
aignificently (p c 0.05) prevented left ventricular free wall (LVFW) creatine
phoaphokinase loss compared to PBS (n =5) or Mab2 (n =5) treated rate
(–0.4 & 1.1 VS3.9 + 1.0 or 4.5 + 0.9 ILJ/mgprotein, respectively). PMN
infiltration into the LVFW was significantly (p < 0.05) inhibited in Mabl -
treatad rats compared to PBS or Mab2 treatad rats (0.2 + 0.2 vs 2.7 +
0.8 or 2.2 + 0.8 U MPO/g wet weight, respectively). Mabl treatment 1 hr
before ischemia (n = 4) or 5 min before reperfusion (n = 8) significantly
(p < 0.05) reduced infarct size (TTC staining; infarct area:area at risk x
100) mmpsrad to PBS (n = 5) or Mab2 (n = 3) treated rats (25 + 6 or
38 + 7 va 76 & 7 or 72 + 4%, respectively). Mabl (n = 5) treatment in
rate undergoing mymardial ischemia (4 hre) and no repedusion significantly
(p < 0.05) reduced infarct size compared PBS (n = 6) treatment (57 + 7
va 94 + 2%, respetiively). Immunohistochemistry demonstrated significant
C3 deposition in treated and untreated hearts. These data suggest that
C5p and C5b-9 are the predominant complement mediators of myocerdial
ischemie/repsrfusion injury. Further, these data suggest that mmplement
inhibition at C5, which presewes the immunoprotactive effects of C3b and
blocks the proinflammatory effects of C5a and C5b-9, may represent a
potentially effective therapeutic intervention for myocardial iachemia and
reperfusion injury.
1988-971 C$rdiOprotectiofl bytheAT,-Rdceptor Blocker
Loastten is Dependent on Bradykinin Receptor
Activation
P.T.Buser, P.Zhu, P. Hornatein, P.R.Allegrini, C.E. Zaugg. Division of
Cardiology University Hospita/, Base/, Swifzer/and
Cardioprotaction of ACE inhibitore in the ischemic and reperfused rat heart
are mainly mediated by bradykinin receptor activation. In recent studies,
Iosartan (Los) - an AT1 receptor blocker – apperantly had no effect on
the brsdykinin system. The aim of this study was to define whether 1)
Loa exerts cardioprotectiva effects during ischemia and reperfusion, and
whather 2) these effects are dependent on bradykinin receptor activation.
In the Langendorlf rat heati, coronary flow (CF), left ventricular developed
preesure (LVP) and the high energy phosphates phosphocreatin (PCr) and
b-adenoain-triphosphate (ATP) by 31phosphoruamagnetic resonance epac-
troscopy were monitonxf during 15 min ischemia and 30 min reperfusion.
Relative changes of the variablea were compared between untreated hearts
(Ctr), hearta treatad with 10-7 M ramiprilat (Ram), 10-8 M Los and the com-
bination of 10-7 M Hoe-140 (Hoe) - a bradykinin receptor antagonist - with
Ram or Los. Compared to baseline values, percent recovery was:
Grmm CF 1%) LVP (“A) PCr (“A} ATP P/o)
Ctr(n = 7) 47+ 3 3s+7“ ’63 * 7 47* 5
Ram (n= 7) 73+ 5* 78+ 6* 107 * 11* S2* 7*
Los(n =7) 66 +3” 81 & s“ 97& 4* 63 i S*
Ram + Hoe (n = 6) 39 i P 13* 3** 34+ llg” 44k 6#
Los+ Hoe (n= 7) 52& 6$ 2s k e# 64 i 5# 50 *#
Mean + SEM, *p <0,05 vs. Ctr, $ p <0.05 vs. conditionwithoutHoe
Los improved postischemic recove~ of CF, LVP, PCr and ATP. Thie was
comparable to the effects of RAM. When combined with Hoe, the cardiopro-
tective effacte of both Los and Ram were aboliahad. Thua, in the rat heart,
Losexedscsrdioprotective effectsduring ischemiaand repetiusion and these
effects are dependent on unrestreined bradykinin receptor activation.
-~ Adeno$if’ieMediat$$ tha,nfarctSi.eLimiting ~ff.ct
of Magnesium in Rabbite
T. Matsuzeka, N. Hasebe, T. Fujino, A. Ido, S. Natori, H. Nakamura,
H. Matsuhashi, K. Kikuchi. Asshikawa Medical College, Asahikawa, Japan
Intravenous magneaium (Mg) therapy haa been reported to reduce mortality
in acute myocsrdial infarction, but the exact mechanism is unknown. The
objsctivea of the present study were to determine whether Mg treatment
can limit myocerdial infarct size (IS), and if so, whether the mechanism is
mediated by endogenous adenosine, a major cardioprotective substance in
ikchemic myocardium.
Four groups of Japanese white rabbits underwent 30 min coronary attery
occlusion (CAO) and 3 hr repeflusion (CAR). Aortic pressure and ECG
were continuously monitored throughout the experiment. (l): Control group
C was untreated. (2): 8PT (6-phenyitheophylline, a broad acting adenoaine
receptor antagonist) group received 6PT (10 mg/kg bolus iv) 25 min before
CAO. (3): Mg group was pre-treated with magnesium sulfate (1 mglk~min
iv) for 30 min before GAO followed by a maintenance dose of Mg (0.14
m@@min) throughout CAR. (4): Mg + 8PT group was given both agents.
Systemic hemodynamice and the incidence of ventricular arrhythmia were
not significantly affected by Mg. Tetrazolium was usad to stain the infarct
area. E/area at risk (AR) ratios were then calculated.
Group c Mg 8PT Mg+SPT
%18/AR 49& s 24+ 11* so* 9 43* 9
*p <0.05 Vsc (n=7) (n= 14) (n=5) (n=7)
Mg treatment significantly reduced IS independent of ita effects on hemo-
dynamics, andthiswasaboiishad by6PT. Thus weconcludethatendogenous
adenosine is at least in part responsible for the infarct size limiting effect of
Mg.
